AYTU BIOPHARMA, INC Form 425: Prospectus or communication for a business combination
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-03-22: Form 425; Description CURRENT REPORT; Document ea138107-8k_aytubioscience.htm.
- 2021-02-10: Form 425; Description FORM 425; Document ea135021-425_aytubio.htm.
- 2021-01-06: Form 425; Description FORM 425; Document aytu20210106_425.htm.
- 2020-12-15: Form 425; Description CURRENT REPORT; Document ea131647-8k_aytubioscience.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2021-03-22 | 425 | CURRENT REPORT | ea138107-8k_aytubioscience.htm | |
| 2021-02-10 | 425 | FORM 425 | ea135021-425_aytubio.htm | |
| 2021-01-06 | 425 | FORM 425 | aytu20210106_425.htm | |
| 2020-12-15 | 425 | CURRENT REPORT | ea131647-8k_aytubioscience.htm | |
| 2020-12-14 | 425 | CURRENT REPORT | ea131480-8k_aytubioscience.htm | |
| 2020-12-10 | 425 | CURRENT REPORT | aytu_8k.htm | |
| 2020-12-10 | 425 | CURRENT REPORT | ea131390-8k_aytubio.htm | |
| 2020-12-10 | 425 | CURRENT REPORT | ea131376-8k_aytubioscience.htm | |
| 2020-12-10 | 425 | CURRENT REPORT | ea131373-8k_aytubioscience.htm | |
| 2020-02-14 | 425 | CURRENT REPORT | f8k021320_aytubioscience.htm | |
| 2020-01-15 | 425 | CURRENT REPORT | f8k0120_aytubioscience.htm | |
| 2020-01-10 | 425 | AMENDMENT NO. 1 TO FORM 8-K | f8k011020a1_aytubioscience.htm | |
| 2019-12-11 | 425 | 425 | aytu_425.htm | |
| 2019-12-03 | 425 | 425 | aytu_425.htm | |
| 2019-10-15 | 425 | Prospectus or communication for a business combination | aytu_425.htm | |
| 2019-10-15 | 425 | 425 | aytu-425.htm | |
| 2019-10-03 | 425 | 425 | aytu_425.htm | |
| 2019-09-26 | 425 | 425 | aytu.htm | |
| 2019-09-23 | 425 | 425 | aytu_425.htm | |
| 2019-09-12 | 425 | 425 | aytu_425.htm | |
| 2019-09-12 | 425 | 425 | aytu_f425.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |